Many argue that phase I cancer trials are a therapeutic option for eligible patients. I question this position and offer a more nuanced view that differentiates between types of trials. Patients seeking treatment might legitimately pursue phase I trials, although labelling all phase I trials as therapeutic contradicts the spirit of evidence-based medicine.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis
Blood Cancer Journal Open Access 01 March 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fukuda, Y. K. et al. Risks and benefits of phase 1 oncology trials, 2001 through 2012. J. Clin. Oncol. 32, 2552–2552 (2014).
Roberts, T. G. et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292, 2130–2140 (2004).
Enzinger, A. C. et al. Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death. J. Pain Symptom Manage. 47, 1078–1090 (2014).
Wright, A. A. et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300, 1665–1673 (2008).
Hay, M. et al. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–51 (2014).
American Society of Clinical Oncology. Insurance Coverage of Clinical Trials. ASCO.org https://www.asco.org/research-progress/clinical-trials/insurance-coverage-clinical-trials (2016).
Marquart, J., Chen, E. Y. & Prasad, V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 4, 1093–1098 (2018).
Temel, J. S. et al. Keeping expectations in check with immune checkpoint inhibitors. J. Clin. Oncol. 36, 1654–1657 (2018).
American Society of Clinical Oncology. Critical role of phase I clinical trials in cancer treatment. J. Clin. Oncol. 15, 853–859 (1997).
Miller, M. Phase I cancer trials: a collusion of misunderstanding. Hastings Cent. Rep. 30, 34–43 (2000).
Anderson, J. A. & Kimmelman, J. Are phase 1 trials therapeutic? risk, ethics, and division of labor. Bioethics 28, 138–146 (2014).
Kimmelman, J. Is participation in cancer phase i trials really therapeutic? J. Clin. Oncol. 35, 135–138 (2016).
Anderson, J. A. & Kimmelman, J. Extending clinical equipoise to phase 1 trials involving patients: unresolved problems. Kennedy Inst. Eth. J. 20, 75–98 (2010).
Pentz, R. D. et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer 118, 4571–4578 (2012).
Truog, R. D. The United Kingdom sets limits on experimental treatments: the case of Charlie Gard. JAMA 318, 1001–1002 (2017).
Acknowledgements
The work of the author is funded by CIHR (PJT-148726).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author serves in a remunerative capacity on a DSMB for a (non-cancer) phase I trial of Ultragenyx.
Rights and permissions
About this article
Cite this article
Kimmelman, J. Phase I trials as therapeutic options: (usually) a betrayal of evidence-based medicine. Nat Rev Clin Oncol 16, 719–720 (2019). https://doi.org/10.1038/s41571-019-0264-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0264-7
This article is cited by
-
Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis
Blood Cancer Journal (2021)
-
Reply to ‘Correcting the ASCO position on phase I clinical trials in cancer’
Nature Reviews Clinical Oncology (2020)
-
Correcting the ASCO position on phase I clinical trials in cancer
Nature Reviews Clinical Oncology (2020)